Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya63450610.26442/00403660.2024.09.202854History of medicineИстория медициныResearch ArticleBiomarkers in acute coronary syndromes: from the origins to the presentБиомаркеры острого коронарного синдрома: от истоков до наших днейhttps://orcid.org/0000-0003-2977-7203OkishevaElena A.ОкишеваЕлена Андреевна
Russian Federation

ассистент каф. факультетской терапии №1

e.okisheva@gmail.comhttps://orcid.org/0000-0002-5820-1759TrushinaOlga Iu.ТрушинаОльга Юрьевна
Russian Federation

доктор медицинских наук, профессор каф. факультетской терапии №1

e.okisheva@gmail.comSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)10102024969Issues of cardiologyВопросы кардиологии9149182207202422072024Copyright ©; 2024, Consilium MedicumCopyright ©; 2024, ООО "Консилиум Медикум"2024Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/634506

Acute coronary syndrome remains the leading cause of death in both patients with coronary artery disease and patients with other diseases (such as diabetes mellitus, chronic kidney disease, inflammatory diseases of various etiologies, and others). Early diagnosis of cardiomyocyte damage and necrosis opens up wide opportunities to improve the prognosis of patients with atherosclerotic lesions of the coronary arteries, and also makes it possible to discharge patients without acute cardiovascular pathology from intensive care units with a high degree of probability. The article discusses the evolution of the research and introduction into broad clinical practice of markers of myocardial damage and necrosis, which have largely improved modern clinical practice.

Острый коронарный синдром продолжает оставаться ведущей причиной смерти пациентов как с ишемической болезнью сердца, так и с иными заболеваниями (сахарный диабет, хроническая болезнь почек, воспалительные заболевания различной этиологии и пр.). Ранняя диагностика повреждения и некроза кардиомиоцитов открывает широкие возможности для улучшения прогноза пациентов с атеросклеротическим поражением коронарных артерий, а также позволяет с высокой долей вероятности переводить из блоков интенсивного наблюдения пациентов без острой сердечно-сосудистой патологии. В статье обсуждается эволюция изучения и внедрения в широкую клиническую практику маркеров повреждения и невроза миокарда, позволивших улучшить современную клиническую практику.

myocardial infarctionacute coronary syndromebiomarkertroponintransaminasesischemiamyocardial injurydiagnosisprognosisинфаркт миокардаострый коронарный синдромбиомаркертропонинтрансаминазыишемияповреждение миокардаатеросклероздиагностикапрогнозThygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69. DOI:10.1093/eurheartj/ehy462LaDue JS, Wroblewski F, Karmen A Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science. 1954;120:497-9. DOI:10.1126/science.120.3117.497World Health Organization Expert Committee. Hypertension and coronary heart disease: classification and criteria for epidemiological studies. First report of the expert committee on cardiovascular diseases and hypertension. WHO Tech Rep Ser. 1959;168.Dreyfus JC, Schapira G, Rasnais J, et al. Serum creatine kinase in the diagnosis of myocardial infarct. Rev Fr Etud Clin Biol. 1960;5:386-7.Roberts R, Sobel BE, Parker CW. Radioimmunoassay for creatine kinase isoenzymes. Science. 1976;194:855-7. DOI: 10.1126/science.982049World Health Organization. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation. 1979;59:607-9. DOI:10.1161/01.cir.59.3.607Danese E, Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 4:194. DOI:10.21037/atm.2016.05.19Ebashi S. Third component participating in the superprecipitation of ‘natural actomyosin’. Nature. 1963;200:1010. DOI:10.1038/2001010a0Greaser ML, Gergely J. Reconstitution of troponin activity from three protein components. J Biol Chem. 1971;246:4226-33. DOI:10.1016/S0021-9258(18)62075-7Bucher EA, Maisonpierre PC, Konieczny SF, et al. Expression of the troponin complex genes: transcriptional coactivation during myoblast differentiation and independent control in heart and skeletal muscles. Mol Cell Biol. 1988;8:4134-42. DOI:10.1128%2Fmcb.8.10.4134Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J. 1987;113:1333-44. DOI:10.1016/0002-8703(87)90645-4Müller-Bardorff M, Hallermeyer K, Schroder A, et al. Improved Troponin T ELISA specific for cardiac Troponin T isoform: assay development and analytical and clinical validation. Clin Chem. 1997;43:458-66.Hallermayer K, Klenner D, Vogel R. Use of recombinant human cardiac Troponin T for standardization of third generation Troponin T methods. Scand J Clin Lab Invest. Suppl. 1999;230:128-31.Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:254-61. DOI:10.1373/clinchem.2009.132654Zhelev Z, Hyde C, Youngman E, et al. Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis BMJ. 2015;350:h15. DOI:10.1136/bmj.h15Røysland R, Kravdal G, Høiseth AD, et al. Cardiac troponin T levels and exercise stress testing in patients with suspected coronary artery disease: the Akershus Cardiac Examination (ACE) 1 study. Clin Sci (Lond). 2012;122(12):599-606. DOI:10.1042/CS20110557Jeremias A, Gibson CM. Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded. Ann Intern Med. 2005;142:786-91. DOI:10.7326/0003-4819-142-9-200505030-00015Garg P, Morris P, Fazlanie AL, et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med. 2017;12(2):147-55. DOI:10.1007/s11739-017-1612-1Миронова О.Ю., Бердышева М.В., Елфимова Е.М. МикроРНК: взгляд клинициста на состояние проблемы. Часть 2. МикроРНК в качестве биомаркера. Евразийский Кардиологический Журнал. 2023;(2):64-71 [Mironova OI, Berdysheva MV, Elfimova EM. MicroRNA: a clinician’s view of the state of the problem. Part 2. MicroRNA as a biomarker. Eurasian Heart Journal. 2023;(2):64-71 (in Russian)]. DOI:10.38109/2225-1685-2023-2-64-71Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659-66. DOI:10.1093/eurheartj/ehq013Wang X, Tian L, Sun Q. Diagnostic and prognostic value of circulating miRNA-499 and miRNA-22 in acute myocardial infarction. J Clin Lab Anal. 2020;34(8):2410-7. DOI:10.1002/jcla.23332Shi S, Yi JL. S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα. Eur Rev Med Pharmacol Sci. 2018;22(12):3925-35. DOI:10.26355/eurrev_201806_15278Li Y, Chen B, Yang X, et al. S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury. Circulation. 2019;140(9):751-64. DOI:10.1161/CIRCULATIONAHA.118.039262Singh N, Rathore V, Mahat RK, Rastogi P. Glycogen Phosphorylase BB: A more Sensitive and Specific Marker than Other Cardiac Markers for Early Diagnosis of Acute Myocardial Infarction. Indian J Clin Biochem. 2018;33(3):356-60. DOI:10.1007/s12291-017-0685-y